ColonScan | A simple to use, accurate and cost-effective blood test for large-scale colon cancer screening

Summary
Universal Diagnostics (UDX) is a biomedicine start-up focused on early detection of cancer using leading-edge technologies. Our mission is to make cancer a curable disease by detecting it early through an accurate, simple to use, and cost-effective diagnostic kit.
During the last 5 years, UDX has been developing a mass spectrometry (MS) based metabolic analysis that allows very cost-effective and accurate detection of metabolic markers in blood, for early detection of different types of cancer.
The first product of the company (the one this proposal is all about) is ColonScan: A simple, noninvasive, accurate (AUC 92%) and inexpensive, blood-based screening test to detect colorectal cancer (CRC) and adenomas (precancerous stages), allowing early detection and cancer prevention.
ColonScan will be highly accurate, easily scalable worldwide, simple to use, non-invasive and inexpensive; ColonScan presents all characteristics and requirements to be adopted as CRC screening program for average risk population since, our technology can be included routinely in normal blood tests at annual or biannual medical check-ups. Moreover, the metabolomics platform developed in ColonScan project can be applied and upscaled to other types of cancer with no cost increase.
CRC is the third most commonly diagnosed and leading cause of cancer death in the world, despite CRC is considered a completely preventable disease. All CRC guidelines recommends regularly (annual or biannual) screening of average risk population (50-85 years old).
This represents a huge market opportunity, which according to our conservative estimations means a target population of 380 Million people and 12 Billion market opportunity.
The ultimate objective of ColonScan Phase 1 project is to assess the feasibility of our business innovation project, under a commercial, technical and financial point of view to minimize any potential risk that might endanger our business plan.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/815686
Start date: 01-05-2018
End date: 30-09-2018
Total budget - Public funding: 71 429,00 Euro - 50 000,00 Euro
Cordis data

Original description

Universal Diagnostics (UDX) is a biomedicine start-up focused on early detection of cancer using leading-edge technologies. Our mission is to make cancer a curable disease by detecting it early through an accurate, simple to use, and cost-effective diagnostic kit.
During the last 5 years, UDX has been developing a mass spectrometry (MS) based metabolic analysis that allows very cost-effective and accurate detection of metabolic markers in blood, for early detection of different types of cancer.
The first product of the company (the one this proposal is all about) is ColonScan: A simple, noninvasive, accurate (AUC 92%) and inexpensive, blood-based screening test to detect colorectal cancer (CRC) and adenomas (precancerous stages), allowing early detection and cancer prevention.
ColonScan will be highly accurate, easily scalable worldwide, simple to use, non-invasive and inexpensive; ColonScan presents all characteristics and requirements to be adopted as CRC screening program for average risk population since, our technology can be included routinely in normal blood tests at annual or biannual medical check-ups. Moreover, the metabolomics platform developed in ColonScan project can be applied and upscaled to other types of cancer with no cost increase.
CRC is the third most commonly diagnosed and leading cause of cancer death in the world, despite CRC is considered a completely preventable disease. All CRC guidelines recommends regularly (annual or biannual) screening of average risk population (50-85 years old).
This represents a huge market opportunity, which according to our conservative estimations means a target population of 380 Million people and 12 Billion market opportunity.
The ultimate objective of ColonScan Phase 1 project is to assess the feasibility of our business innovation project, under a commercial, technical and financial point of view to minimize any potential risk that might endanger our business plan.

Status

CLOSED

Call topic

EIC-SMEInst-2018-2020

Update Date

27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
H2020-EU.2.1.0. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Cross-cutting calls
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.0. INDUSTRIAL LEADERSHIP - Innovation In SMEs - Cross-cutting calls
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.0. Cross-cutting call topics
H2020-EIC-SMEInst-2018-2020
H2020-SMEInst-2018-2020-1